The Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS Clinical Trials Unit, previously known as the Harvard Medical School/Boston Medical Center (HMS/BMC) AIDS CTU, comprises a consortium of clinical research sites (CRS) affiliated with the AIDS Clinical Trials Group (ACTG) network leadership group. The CRSs are located at Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH), Beth Israel-Deaconess Medical Center (BIDMC), and Boston Medical Center (BMC), with an administrative component located at MGH. Throughout its 19-year history, investigators of the HMS/BMC AIDS CTU have made major contributions to therapeutic research in AIDS and have played a critical role in the scientific leadership of the ACTG: pivotal studies demonstrating clinical efficacy of combination antiretroviral therapy, protease inhibitor therapy, and combination therapy of HCV in co-infected persons all have been led by HMS/BMC AIDS CTU investigators. We propose a comprehensive, integrated clinical and translational research program that addresses five of the six priority areas described in the Network Leadership Group RFA (AI-05-001), including: 1) translational research/drug development;2) optimization of clinical management, including co-morbidities;3) vaccine development (therapeutic vaccines);4) prevention of mother-to-child transmission (in collaboration with the Boston IMPAACT Clinical Trials Unit);and 5) prevention of HIV-1 infection. In addition, the Partners/Harvard/BMC AIDS CTU has formed mentoring partnerships with the Botswana CTU in Gaborone and the Chinese Academy of Medical Sciences/Peking Union Medical College CTU in Beijing through which investigators and research staff of the Partners/Harvard/BMC AIDS CTU provide training and guidance in the conduct of ACTG trials. Recruitment of women and subjects from traditionally underrepresented minority groups is a top priority of the Partners/Harvard/BMC AIDS CTU. This goal is aided by location of two of our CRSs (BWH and BMC in predominantly minority neighborhoods, and outreach efforts coordinated with our Community Advisory Board. Results of the studies proposed in this application will have a profound impact on public health by improving clinical care, preventing or delaying HIV disease progression, and reducing or eliminating the morbidity and mortality associated with HIV-1 infection and its associated complications. ADMINISTRATIVE COMPONENT

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069472-04
Application #
7743024
Study Section
Special Emphasis Panel (ZAI1-TP-A (M2))
Program Officer
Germuga, Donna E
Project Start
2007-02-01
Project End
2013-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
4
Fiscal Year
2010
Total Cost
$3,027,841
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Coleman, Jenell S; Cespedes, Michelle S; Cu-Uvin, Susan et al. (2016) An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. J Low Genit Tract Dis 20:31-7
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Cillo, Anthony R; Hilldorfer, Benedict B; Lalama, Christina M et al. (2015) Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS 29:2121-9
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82

Showing the most recent 10 out of 126 publications